Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2001
09/20/2001WO2001068693A1 A novel polypeptide, human cannabinoid receptor protein 7 and the polynucleotide encoding thereof
09/20/2001WO2001068691A1 A novel polypeptide, human fd11 and the polynucleotide encoding there of
09/20/2001WO2001068689A1 A novel polypeptide, human hypoxia-inducible factor 1 alpha subunit 13 and the polynucleotide encoding thereof
09/20/2001WO2001068688K1 A novel polypeptide, a human protein kinase tak1-27 and the polynucleotide encoding the polypeptide
09/20/2001WO2001068688A1 A novel polypeptide, a human protein kinase tak1-27 and the polynucleotide encoding the polypeptide
09/20/2001WO2001068687A1 A novel polypeptide-clathrin light chain 21 and the polynucleotide encoding said polypeptide
09/20/2001WO2001068686A1 A novel polypeptide-human mannosephosphate isomerase 16 and the polynucleotide encoding said polypeptide
09/20/2001WO2001068685A1 A novel polypeptide-human sperm specific protein em1,em6-48 and the polynucleotide encoding said polypeptide
09/20/2001WO2001068684A1 A novel polypeptide-human protocadherins 14 and the polynucleotide encoding said polypeptide
09/20/2001WO2001068682A1 Self antigen vaccines for treating b cell lymphomas and other cancers
09/20/2001WO2001068681A2 Altered ion channel proteins
09/20/2001WO2001068679A2 Peptides targeting specifically tumor-derived endothelial cells
09/20/2001WO2001068678A2 Peptides that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
09/20/2001WO2001068677A2 Derivatives of breast canacer antigen her-2 for therapeutical use
09/20/2001WO2001068676A2 Lhrh-antagonists, production and use thereof as medicament
09/20/2001WO2001068675A2 Treatment of rosacea
09/20/2001WO2001068670A2 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof
09/20/2001WO2001068667A1 Arrest of proliferation of highly glycolytic tumors
09/20/2001WO2001068666A1 Tcl1 enhances akt kinase activity and mediates its nuclear translocation
09/20/2001WO2001068655A2 Caprolactam derivatives and uses thereof
09/20/2001WO2001068148A1 Systemic gene delivery vehicles for the treatment of tumors
09/20/2001WO2001068146A2 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
09/20/2001WO2001068145A2 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
09/20/2001WO2001068144A2 Biodegradable immunomodulatory formulations and methods for use thereof
09/20/2001WO2001068139A1 Formulation solubilizing water-insoluble agents and preparation method thereof
09/20/2001WO2001068135A2 Compositions and methods for affecting osteogenesis
09/20/2001WO2001068130A1 Method and composition for treating airway hyperresponsiveness
09/20/2001WO2001068127A1 Use of growth hormone in low dose
09/20/2001WO2001068126A2 Methods and compositions for treating premature rupture of fetal membranes
09/20/2001WO2001068125A2 Methods and compositions for the treatment and prevention of erectile dysfunction
09/20/2001WO2001068124A2 Suppression of vascular disorders by mucosal administration of heat shock protein peptides
09/20/2001WO2001068123A2 Monocyte chemoattractant activity of galectin-3
09/20/2001WO2001068122A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia'
09/20/2001WO2001068121A1 Remedies for allergic diseases
09/20/2001WO2001068120A2 Uses of bombesin receptor 3
09/20/2001WO2001068117A2 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
09/20/2001WO2001068115A1 Process for producing peptide sequences possessing anti-hypertension activity
09/20/2001WO2001068114A1 Novel peptides with anti-hypertensive activity
09/20/2001WO2001068113A1 Anti-hypertensive peptides
09/20/2001WO2001068112A2 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
09/20/2001WO2001068109A1 Modified factor viii
09/20/2001WO2001068093A1 Use of glucosylceramide synthesis inhibitors in brain cancertherapy
09/20/2001WO2001068069A2 Pharmaceutical composition comprising paracetamol
09/20/2001WO2001068068A2 Compounds capable of binding with the cytoskeleton
09/20/2001WO2001068053A2 Methods and compositions for treating and preventing posterior segment ophthalmic disorders
09/20/2001WO2001067889A1 Diabetic nutritionals
09/20/2001WO2001067862A1 Adrenergic receptor overexpression in airway tissues for the treatment of airway obstructive diseases
09/20/2001WO2001032029A3 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein
09/20/2001WO2001031033A3 Protease from lucila sericata and its use in treatment of wounds
09/20/2001WO2001030379A3 Compositions and methods for preventing and treating transplant rejection
09/20/2001WO2001029070A8 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
09/20/2001WO2001028579A3 Inhibitors of proteasomal activity for stimulating bone and hair growth
09/20/2001WO2001028533A3 PRODUCTS AND METHODS FOR ACTIVATING PPARη-RXR AND UP-REGULATING MONOCYTE/MACROPHAGE CD36 FOR THE TREATMENT OF MALARIA
09/20/2001WO2001019851A3 Opaminergic neuronal survival-promoting factors and uses thereof
09/20/2001WO2001019850A3 Nrage nucleic acids and polypeptides and uses thereof
09/20/2001WO2001018051A3 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
09/20/2001WO2001017479A3 Methods and compositions for preventing and treating prostate disorders
09/20/2001WO2001016603A3 Analysis and treatment of body weight and eating disorders
09/20/2001WO2001016317A3 Polycyclic aromatic hydrocarbon induced molecules
09/20/2001WO2001016167A3 Beta-catenin, tcf-4, and apc interact to prevent cancer
09/20/2001WO2001016165A3 Apoptin-associating protein
09/20/2001WO2001014593A3 A method for producing quality assured biological sample and composition containing the same
09/20/2001WO2001014581A3 Hdac4 and hdac5 in the regulation of cardiac gene expression
09/20/2001WO2001014424A3 Human ctla-4 antibodies and their uses
09/20/2001WO2001013887A3 Phospholipin gel
09/20/2001WO2001012661A3 RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
09/20/2001WO2001010456A3 Peptides that block viral infectivity and methods of use thereof
09/20/2001WO2001007065B1 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES
09/20/2001WO2001005971A3 Secreted polypeptides and corresponding polynucleotides
09/20/2001WO2001002540A9 Adenoviral vectors for treating disease
09/20/2001WO2000046246A8 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
09/20/2001WO2000045771A9 Suppression of transformation of cells by the transcription factor egr
09/20/2001WO2000044774A9 Inhibition of stat3 signal transduction for human cancer therapy
09/20/2001WO2000043028A9 Method of treating chronic cardiac disease
09/20/2001WO2000040204A9 Methods for treating cystic fibrosis
09/20/2001WO2000037491A3 Dnas encoding proteins with signal sequences
09/20/2001WO2000037490A3 Outer surface proteins, their genes, and their use
09/20/2001WO2000024419A9 Methods for enhancing wound healing
09/20/2001WO2000018899A3 Angiotensin converting enzyme homolog and its use
09/20/2001WO2000009537A3 Compounds having growth hormone releasing activity
09/20/2001US20010023289 Detecting nucleic acids encoding mammalian polypeptides,antisense oligonucleotides.screening agonists or antagonists of receptors
09/20/2001US20010023287 Induction of endhotelial procoagulant is inhibited and induction of fibrin deposition is enhanced; cytotoxicity and receptor binding activities unaffected; monoclonal antibody
09/20/2001US20010023256 Reducing concentration of oxygen metabolites
09/20/2001US20010023245 Ophthalmic composition including a neurotrophic factor for treating optic nerve function disorders and method for treating optic nerve function disorders
09/20/2001US20010023244 Thrombin inhibitors
09/20/2001US20010023243 Method for treating parathyroid disorders
09/20/2001US20010023242 Polypeptide from snake venom
09/20/2001US20010023241 Complexing tyrosine kinase receptor; respiratory system disorders
09/20/2001US20010023240 Compounds and compositions for delivering active agents
09/20/2001US20010023070 Isolated polypeptide; genetic engineering
09/20/2001US20010023064 yfjO
09/20/2001US20010022979 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions
09/20/2001US20010022977 Administering apoptosis agent
09/20/2001US20010022971 IBD-associated microbial nucleic acid molecules
09/20/2001US20010022969 Sepsis therapy
09/20/2001US20010022964 Fast dissolving orally consumable films
09/20/2001DE10012732A1 Thrombin composition, for use as hemostatic or as a component of fibrin glues, comprises non-covalently bonded inhibitor for stabilization
09/20/2001DE10012259A1 Antiviral combination based on dihydropyrimidine derivatives and non-dihydropyrimidine HBV antiviral agents, are useful for treatment of HBV infections
09/20/2001DE10011358A1 Producing a modified L-form bacterial strain by culturing the strain in complex medium and subjecting it to temperature stress, provides bacteria useful to produce recombinant proteins
09/20/2001CA2534391A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same